269 related articles for article (PubMed ID: 15095304)
1. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.
Heuser C; Guhlke S; Matthies A; Bender H; Barth S; Diehl V; Abken H; Hombach A
Int J Cancer; 2004 Jun; 110(3):386-94. PubMed ID: 15095304
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells.
Heuser C; Diehl V; Abken H; Hombach A
Int J Cancer; 2003 Sep; 106(4):545-552. PubMed ID: 12845650
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis.
Hombach A; Heuser C; Abken H
Int J Cancer; 2005 Jun; 115(2):241-7. PubMed ID: 15688386
[TBL] [Abstract][Full Text] [Related]
4. Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach.
Schlapschy M; Gruber H; Gresch O; Schäfer C; Renner C; Pfreundschuh M; Skerra A
Protein Eng Des Sel; 2004 Dec; 17(12):847-60. PubMed ID: 15708864
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
[TBL] [Abstract][Full Text] [Related]
6. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
Cancer Res; 1998 Mar; 58(6):1116-9. PubMed ID: 9515791
[TBL] [Abstract][Full Text] [Related]
7. An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack.
Jahn T; Zuther M; Friedrichs B; Heuser C; Guhlke S; Abken H; Hombach AA
PLoS One; 2012; 7(9):e44482. PubMed ID: 23028547
[TBL] [Abstract][Full Text] [Related]
8. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
Renner C; Pfreundschuh M
J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
[TBL] [Abstract][Full Text] [Related]
9. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
Hristodorov D; Nordlohne J; Mladenov R; Huhn M; Fischer R; Thepen T; Barth S
Br J Haematol; 2014 Jan; 164(2):251-7. PubMed ID: 24164493
[TBL] [Abstract][Full Text] [Related]
10. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
[TBL] [Abstract][Full Text] [Related]
11. Generation of the single chain antibody fragment conserves the idiotypic profile of the anti-CD30 monoclonal antibody HRS3.
Hombach A; Pohl C; Heuser C; Sircar R; Koch D; Diehl V; Abken H
Scand J Immunol; 1998 Nov; 48(5):497-501. PubMed ID: 9822258
[TBL] [Abstract][Full Text] [Related]
12. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
13. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells.
Watanabe M; Ogawa Y; Ito K; Higashihara M; Kadin ME; Abraham LJ; Watanabe T; Horie R
Am J Pathol; 2003 Aug; 163(2):633-41. PubMed ID: 12875982
[TBL] [Abstract][Full Text] [Related]
14. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
[TBL] [Abstract][Full Text] [Related]
15. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
[TBL] [Abstract][Full Text] [Related]
16. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells.
Horie R; Watanabe T; Morishita Y; Ito K; Ishida T; Kanegae Y; Saito I; Higashihara M; Mori S; Kadin ME; Watanabe T
Oncogene; 2002 Apr; 21(16):2493-503. PubMed ID: 11971184
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells.
Horie R; Watanabe T; Ito K; Morisita Y; Watanabe M; Ishida T; Higashihara M; Kadin M; Watanabe T
Am J Pathol; 2002 May; 160(5):1647-54. PubMed ID: 12000717
[TBL] [Abstract][Full Text] [Related]
19. First Hodgkin cell line L428 and the CD30 antigen: their role for diagnostic and treatment of CD30-positive neoplasms.
Stein H; Diehl V
Hematol Oncol Clin North Am; 2014 Feb; 28(1):1-11. PubMed ID: 24287063
[TBL] [Abstract][Full Text] [Related]
20. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.
van den Berg A; Visser L; Poppema S
Am J Pathol; 1999 Jun; 154(6):1685-91. PubMed ID: 10362793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
